Boothbay Fund Management’s Solid Biosciences SLDB Stock Holding History

Boothbay Fund Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$199K	Sell	19,949 -67,100	-77%	-$509K	﹤0.01%	1937
2026 Q1	$627K	Buy	87,049 +34,250	+65%	+$220K	0.01%	1211
2025 Q4	$298K	Sell	52,799 -16,281	-24%	-$88.2K	﹤0.01%	1430
2025 Q3	$426K	Buy	+69,080	New	+$404K	0.01%	1259
2025 Q2	–	Sell	-69,874	Closed	-$259K	–	1739
2025 Q1	$259K	Buy	+69,874	New	+$299K	0.01%	1097
2022 Q2	–	Sell	-3,985	Closed	-$72K	–	2626
2022 Q1	$72K	Hold	3,985	–	–	﹤0.01%	2145
2021 Q4	$105K	Hold	3,985	–	–	﹤0.01%	1708
2021 Q3	$143K	Buy	+3,985	New	+$169K	﹤0.01%	1712
2021 Q1	–	Sell	-5,020	Closed	-$571K	–	1763
2020 Q4	$571K	Buy	5,020 +304	+6%	+$19.2K	0.02%	693
2020 Q3	$144K	Hold	4,716	–	–	0.01%	966
2020 Q2	$207K	Buy	4,716 +1,208	+34%	+$50.2K	0.01%	793
2020 Q1	$126K	Buy	3,508 +2,673	+320%	+$132K	0.01%	707
2019 Q4	$56K	Buy	+835	New	+$92.1K	﹤0.01%	798

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Boothbay Fund Management's SLDB Position: Q2 2026 in Review

Boothbay Fund Management reduced its Solid Biosciences (SLDB) stake by 77% in Q2 2026, selling an estimated $509K and leaving 19,949 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #1937.

Boothbay Fund Management first reported a position in SLDB in Q4 2019 and has held it in 13 quarters since. The position peaked at $627K in Q1 2026. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Boothbay Fund Management held 19,949 shares of Solid Biosciences worth $199K as of Q2 2026.
Boothbay Fund Management sold 67,100 Solid Biosciences shares in Q2 2026, an estimated $509K.
Solid Biosciences made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1937 holding.
Boothbay Fund Management first reported a position in Solid Biosciences in Q4 2019 and has held it in 13 quarters since.
Boothbay Fund Management's Solid Biosciences position peaked at $627K in Q1 2026.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.